Zenas BioPharma, Inc. (ZBIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $28.77
- As of
Kresmion compiles this page from ZBIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Zenas BioPharma, Inc. (ZBIO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-13.
See the full ZBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ZBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the ZBIO dossierActive events for ZBIO
- high13F: funds added
3 tracked funds increased ZBIO this 2026Q2, institutional consensus
- mediumEarnings below estimates
Q2-2026: Missed consensus by 12.5%, EPS $-1.29 vs $-1.147 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in ZBIO
- high13F: large increase
CITADEL ADVISORS LLC added +786% to ZBIO (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 83% of ZBIO (2026Q2)
FREE, NO ACCOUNT
Every event on ZBIO, as it fires
You are seeing 5 of 16 events recorded on ZBIO since 2026-06-05.
The five above landed across 3 days. The other 11 were recorded on 3 other days. 8 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ZBIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 98937LAA3 · 2026Q2 | $26M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 98937L105 · 2026Q2 | $20.7M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 98937L105 · 2026Q2 | $16.8M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 98937L105 · 2026Q2 | $5M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 98937L105 · 2026Q2 | $410K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 98937LAA3 · 2026Q2 | $239K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ZBIO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ZBIO against its peers
ZBIO's operating margin of -3830.6% ranks in the 9th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | ZBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 10.0M USD | 137M USD | 10 | 14 |
| Gross margin | n/a | 93.5% | n/a | 7 |
| Operating margin | -3830.6% | -79.5% | 9 | 15 |
| Net margin | -3777.4% | -77.4% | 9 | 16 |
| Return on equity | -156.0% | -30.2% | 3 | 15 |
Peers (19): NTLA, MLYS, MAZE, VIR, MESO, QURE, NBTX, ABSI, SRPT, SLS, STOK, SEPN, NVAX, CMPS, RARE, ZYME, IMCR, VCEL, LKFT. Left out: TRAX (no annual filing), COAG (no annual filing), BRVE (no annual filing), GENB (no annual filing), ADRX (no annual filing), KLRA (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ZBIO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ZBIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.